‹ ›
MYP_058737
← PREVIOUS NEXT → BACK
Basic Information
EK1
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Standard
36 amino acids
C196H317N43O64S
Standard
Sequence
SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL
Physicochemical Analysis
4331.93 Da
4.36
-5.52
-5.76
-0.1534
-0.43
0.75
-0.05
22.73
119.17
0.0833
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1772.25
-9.98
59.0
60.0
156.0
304.0
3.0
37.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0292613 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
inhibit the replication of HCoV-229E in Huh-7 cells
4.375 μM
IC50
PaperInhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. PMID: 32231345 PMID35087243;32231345;30989115;32047258 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0293736 VERIFIED: YES
Provenance & Taxonomy
Human coronavirus OC43 [Virus]
HR2-derived fusion inhibitor
31631
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome coronavirus 2
0.19 μM
IC50
PaperFusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein PMID32047258 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32047258/
RECORD: Rec_0300110 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV Fusion inhibition
SARS-CoV | Huh-7 cells
0.4093 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperInhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. | Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L. | Cell Res. 2020 Apr;30(4):343-355. | DOI:10.1038/s41422-020-0305-x | PMID:32231345 PMID32231345 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32231345/
RECORD: Rec_0300485 VERIFIED: YES
Provenance & Taxonomy
Human coronavirus OC43 [Virus]
HR2-derived fusion inhibitor
31631
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Cholesterol conjugation
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome coronavirus 2
0.0568 μM
IC50
PaperInhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion PMID32231345 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32231345/
RECORD: Rec_0301692 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of cell-cell infusion in Caco2 cells
0.07499 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. | Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. | Cell Res. 2022 Apr;32(4):404-406. | DOI:10.1038/s41422-022-00617-x | PMID:35087243 PMID35087243 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
FIRST PREV 1 ... 20 21 22 23 24 ... 32 NEXT LAST
Showing 5 records on this page · Page 22 of 32